Allopurinol pharmacogenetics: assessment of potential clinical usefulness. - Wikidata - awgldk - TriplyDB

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

http://www.wikidata.org/entity/Q34236067

about

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Pharmacogenetic testing: Current Evidence of Clinical Utility.Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Integrating pharmacogenetic information and clinical decision support into the electronic health record.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States.Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.Applications of pharmacogenomics in regulatory science: a product life cycle review.Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population.HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.The British Society for Rheumatology Guideline for the Management of Gout.Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective

P2860

Q24612292-7E17682B-CD47-44F7-8FAF-33D4DC6218A1 Q24626941-4BCBDFB6-EDD5-4A8C-9DEE-20B3A699E1E2 Q34557668-2D7C419D-EBD1-40B5-B903-21EA4CCDD409 Q37151528-E3753914-2615-4A12-B8C4-B1F98165EE75 Q37507172-7FD29C17-9DE0-48DB-A1C7-E5910D9AC904 Q37697237-37CE5997-036C-4664-ACAC-E7EE643BA333 Q37715400-6EAC3834-CE7C-4072-B5D2-D158BF96C259 Q38123116-B9220CB0-7398-49BC-B405-084DA11F3F1F Q38219092-8C829DF9-0C9F-498C-97A5-3CB9D4BB04F6 Q39132630-5EB50FCC-5A8C-459B-A44C-8DC91D5D20D7 Q39741682-F4A85AC0-922B-488C-B7F3-BC92485C9643 Q40915728-57BA2FA4-7411-4F46-A861-3DC25C38A52E Q47284170-B0CB0854-5326-4038-B4FC-3FB2A7A0CAF1 Q47431684-0FDAA72F-8522-4696-A3A3-0EDF3C8FE51A Q51060800-9DE6044E-4A29-417C-9E54-33FC8D6EAA87 Q54664040-473F1376-D290-4DAC-A7B9-DC90695843CC Q55060116-1F9699C0-F11D-4358-B04E-C8DE2908FA86 Q58698797-EB211BF7-198A-4C92-A878-D5E4F15F9D38

P2860

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

http://www.wikidata.org/entity/Q34236067

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@ast

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@en

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@nl

type

label

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@ast

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@en

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@nl

prefLabel

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@ast

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@en

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@nl

P1433

Q34236067-CA3D6E68-C954-4AD3-80D6-904E21FB8048

P1476

Q34236067-678E0DFD-51CE-4227-B5B5-B4CABE5F3092

P2093

Q34236067-01AB5BDF-146D-4172-88BC-80EFD8E6DE17

Q34236067-06A7972A-045D-4FA1-A578-BB28733D27B7

Q34236067-24C72F03-9764-4C16-8BFE-943297D918F5

Q34236067-774BAC9D-8AC0-4794-82A0-0F7DAB43DBFD

Q34236067-821B38A7-FEFB-49EE-BDAB-0231E433C4F0

Q34236067-A8130466-6B0E-4F1C-8243-6CE7BCB95628

Q34236067-CC4B2229-81EE-4F6D-BC38-73FB4A634775

Q34236067-F54D8C0E-8AB5-4CF8-BF0A-837549E1829E

P2860

Q34236067-00EF7272-80A2-4DA0-A841-DA0D08DB70FD

Q34236067-04E155BC-F5FE-4A83-AE83-A4D1D0E59084

Q34236067-06257820-C23E-4A1F-BEBD-D1C239A2F3F4

Q34236067-1C478A46-CDB3-4B14-82C3-5D50F3DA367F

Q34236067-2B115125-1822-4647-B9FA-893345BA7A40

Q34236067-3C9AAFB5-416A-4E8C-8F6A-058A48522029

Q34236067-434E7152-1749-47CD-9AA3-7B0597ED7A22

Q34236067-58B60323-87D5-4037-9193-21361DD9F331

Q34236067-748AF528-51F7-4C06-BEDB-1278DDAAB4FC

Q34236067-938C12B0-8F90-43E0-8B38-CA56402DAC3D

P304

Q34236067-3900691B-0D3A-4946-A5CE-293B79EBE522

P31

Q34236067-1DC5C445-D0E3-4F8D-8412-5E586B7211DA

P356

Q34236067-5657BF52-823B-4AC3-8AD1-DFCC5D291BC0

P433

Q34236067-EE25507D-504A-4EDA-A40F-57108C4D9102

P478

Q34236067-9126E11F-8ED3-44D2-803E-9D53358A7E3E

P577

Q34236067-97E501A9-606B-4FB3-8070-FC7050EE8DAD

P698

Q34236067-0E59E2D9-2A6C-472A-9598-2C626181D74A

P356

P1433

Pharmacogenomics

P1476

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

@en

P2093

Hobart Rogers

http://www.w3.org/2001/XMLSchema#string

Issam Zineh

http://www.w3.org/2001/XMLSchema#string

Jenna Lyndly

http://www.w3.org/2001/XMLSchema#string

Lois A La Grenade

http://www.w3.org/2001/XMLSchema#string

Michael A Pacanowski

http://www.w3.org/2001/XMLSchema#string

Padmaja Mummaneni

http://www.w3.org/2001/XMLSchema#string

Shashi Amur

http://www.w3.org/2001/XMLSchema#string

Stephen H Chang

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Measuring inconsistency in meta-analyses

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Update on emerging urate-lowering therapies.

Pharmacogenetics and human genetic polymorphisms.

P304

1741-1749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.11.131

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22118056

http://www.w3.org/2001/XMLSchema#string